Evidence map›Paper›PMID 24717973›Full record

ArticleScientific reports2014

Performance-enhanced mesenchymal stem cells via intracellular delivery of steroids.

James A Ankrum, Riddhi G Dastidar, Joon Faii Ong, Oren Levy, Jeffrey M Karp

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 1 pooled it
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 1 synthesis or guideline pooled it, 84 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Persistent tailoring of MSC activation through genetic priming.Molecular therapy. Methods & clinical development · 2024
    Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Therapeutic implications of transplanted-cell death.Nature biomedical engineering · 2021
    Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

James A Ankrum1] Center for Regenerative Therapeutics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA [2] Harvard-MIT Division of Health Sciences & Technology, Cambridge, MA 02139, USA.
Riddhi G DastidarCenter for Regenerative Therapeutics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Joon Faii OngCenter for Regenerative Therapeutics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Oren LevyCenter for Regenerative Therapeutics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Jeffrey M Karp1] Center for Regenerative Therapeutics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA [2] Harvard-MIT Division of Health Sciences & Technology, Cambridge, MA 02139, USA [3] Harvard Stem Cell Institute, 1350 Massachusetts Avenue, Cambridge, MA 02138, USA.
Brigham and Women's Hospital · USHarvard University · USHarvard–MIT Division of Health Sciences and Technology · US

Funding

Engineered Induction of a Stem Cell Homing ResponseR01HL095722 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI KARP, JEFFREY MICHAEL · 2010 to 2018
$3.9M
NHLBI NIH HHS HL095722,NHLBI NIH HHS R01 HL095722
6 · The paper itself

Abstract

Inadequate immunomodulatory potency of mesenchymal stem cells (MSC) may limit their therapeutic efficacy. We report glucocorticoid steroids augment MSC expression and activity of indoleamine-2,3-dioxygenase (IDO), a primary mediator of MSC immunomodulatory function. This effect depends on signaling through the glucocorticoid receptor and is mediated through up-regulation of FOXO3. Treatment of MSCs with glucocorticoids, budesonide or dexamethasone, enhanced IDO expression following IFN-γ stimulation in multiple donors and was able to restore IDO expression in over-passaged MSCs. As IDO enhancement was most notable when cells were continuously exposed to budesonide, we engineered MSC with budesonide loaded PLGA microparticles. MSC efficiently internalized budesonide microparticles and exhibited 4-fold enhanced IDO activity compared to budesonide preconditioned and naïve MSC, resulting in a 2-fold improvement in suppression of stimulated peripheral blood mononuclear cells in an IDO-dependent manner. Thus, the augmentation of MSC immune modulation may abrogate challenges associated with inadequate potency and enhance their therapeutic efficacy.

Indexed as

Anti-Inflammatory AgentsBudesonideCell ProliferationCells, CulturedDexamethasoneGlucocorticoidsHLA-A AntigensHLA-B AntigensHLA-C AntigensHLA-DR AntigensHumansIndoleamine-Pyrrole 2,3,-DioxygenaseInterferon-gammaMesenchymal Stem CellsNanoparticlesRNA InterferenceAnti-Inflammatory AgentsBudesonideDexamethasoneGlucocorticoidsHLA-A AntigensHLA-B AntigensHLA-C AntigensHLA-DR AntigensIndoleamine-Pyrrole 2,3,-DioxygenaseInterferon-gammaRNA, Small Interfering

Identifiers

PMID24717973
PMCPMC3982175
OpenAlexW2165703796

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.